biopharmatips

A biosimilar is a biotherapeutic which is almost like an authorized product in relation to the ingredients used and has no significant differences in safety and efficacy. Biologics are much larger than a small molecule, more complex fundamentally and they are created in living cells, then removed and cleaned. In contrast, small molecule medicines are produced solely through chemical synthesis. According to a McKinsey report, the biosimilars market will be thrice its current size by 2020. It shows how these drugs can transform the healthcare industry. According to the Biosimilars Council report, biosimilars can potentially save costs by up to $250 billion in the coming decade.  Challenges in Biosimilar Development Pharma companies around the world face several challenges to cut patient costs. Some of the common challenges that biosimilar companies face in packaging and processing are the variability of large molecules and offering the FDA with enough proof of clini